Appropriate sedation is essential for colonoscopies, commonly conducted for diagnostic and therapeutic reasons, to ensure patient comfort, procedure efficiency, and operator satisfaction. The optimal properties of a sedative medicine include rapid onset, sufficient depth of drowsiness, swift recovery, and minimal side effects, particularly with the circulatory and respiratory systems [1, 2]. Due to its brief half-life and rapid onset of action, propofol has eclipsed all other drugs employed for patient sedation during procedures in recent years. Nonetheless, its usage may be unsafe, especially in high-risk patients, owing to adverse effects including dose-dependent hypotension, respiratory depression, and the lack of a specific reversal agent [3].
Remimazolam, a novel ultra-short-acting benzodiazepine, has demonstrated potential as a substitute for conventional procedural sedation in recent years. It possesses a predictable pharmacokinetic profile and minimal accumulation due to rapid degradation by tissue esterases into an inactive metabolite. Remimazolam maintains steady blood pressure and heart rate while diminishing the risk of respiratory depression in comparison to propofol. Another safety advantage is that flumazenil can counteract its effects [4, 5].
Understanding the relationship between drug concentration and therapeutic effect necessitates pharmacokinetic-pharmacodynamic (PK-PD) modeling. It enables the comparison of different sedative medications based on their safety and efficacy, allowing for the improvement of dose protocols. In patients undergoing colonoscopy, there is a deficiency of comparative data about the pharmacokinetic-pharmacodynamic characteristics of propofol and remimazolam, despite their prevalent application [6, 7].
This research sought to assess the pharmacokinetic and pharmacodynamic characteristics of propofol and remimazolam in patients undergoing colonoscopy. The study aims to evaluate the therapeutic efficacy of various medicines in procedural sedation by examining variations in start and recovery durations, depth of drowsiness, hemodynamic effects, and adverse events.

This prospective, randomized comparison study was performed. This study was conducted at the department of Pharmacology, Deccan College of Medical Sciences, Santhosh Nagar, Hyderabad, Telangana, between December 2021 to September, 2022. 40 adult patients scheduled for elective colonoscopy were included following the acquisition of written informed permission. Ethical approval was secured from the Institutional Ethics Committee before the initiation of the project. Patients were randomly assigned to two equal groups: Group R (n = 20): Administered remimazolam for procedural sedation. Group P (n = 20): Administered propofol for procedure sedation. All patients had a pre-anesthetic assessment, encompassing medical history, physical examination, and pertinent laboratory tests. Inclusion Criteria: ● Patients aged 18–65 years ● Patients of ASA physical status I and II ● Patients scheduled for elective colonoscopy ● Patients willing to provide written informed consent Exclusion Criteria: ● Patients with severe cardiopulmonary disease (ASA III or above) ● Known allergy or contraindication to benzodiazepines or propofol ● Patients with hepatic or renal impairment ● Pregnant or lactating women ● Patients on medications affecting central nervous system (e.g., sedatives, opioids) ● Patients unwilling to participate in the study Statistical Analysis: We used statistical tools to examine the data that was entered into Microsoft Excel. Mean ± standard deviation (SD) was used to represent continuous variables, and frequencies and percentages were used to represent categorical variables. We used Student's t-test for continuous variables and either Fisher's exact test or Chi-square test for categorical variables to compare the two groups. Nonlinear mixed-effects modeling was used to do pharmacokinetic-pharmacodynamic (PK-PD) simulation. Statistical significance was determined by a p-value less than 0.05.

A total of 40 patients scheduled for elective colonoscopy were randomly assigned to Group R (Remimazolam, n = 20) and Group P (Propofol, n = 20). The initial traits of both groups were similar. The pharmacokinetic and pharmacodynamic parameters, as well as clinical outcomes, are delineated below.

Table 1: Baseline Demographic Characteristics

In terms of age, gender distribution, body mass index, and ASA status, both groups were similar. The results showed no statistically significant changes, suggesting that the randomization was done correctly.

Table 2: Pharmacokinetic Parameters

Faster metabolism and less drug buildup were indicated by Remimazolam's greater clearance and shorter elimination half-life as compared to propofol.

Table 3: Pharmacodynamic Parameters

Efficient sedation was obtained by both groups. Remimazolam patients, on the other hand, returned to baseline consciousness far more quickly, suggesting a shorter recovery period.

Table 4: Hemodynamic and Respiratory Parameters

Remimazolam improved hemodynamic stability while reducing systolic blood pressure much less. The propofol group had a higher incidence of respiratory depression and desaturation episodes.

Table 5: Adverse Events

Remimazolam resulted in a decreased occurrence of side effects. Significantly greater rates of injection discomfort and hypotension were observed in the propofol group, suggesting that remimazolam had a better tolerability profile.

The safety and comfort of the patient during the colonoscopy procedure depends on the level of sedation used. The perfect sedative would have a short onset time, a relatively predictable depth of sleepiness, a speedy recovery time, and few side effects. With a focus on safety, efficacy, and recovery characteristics, we evaluated the pharmacokinetic-pharmacodynamic (PK-PD) profiles of propofol and remimazolam in 40 patients going through colonoscopy [8-10].

The similarity in the patients' baseline characteristics between the two groups suggests that the randomization was appropriate and that confounding factors were minimized. The two sedatives could thus be compared in an accurate manner [11, 12].

Remimazolam had a far better pharmacokinetic profile than propofol, with a shorter elimination half-life and substantially greater clearance, which was one of the most important conclusions drawn from the study. Reduced drug buildup and improved titration during operations are both result of this fast metabolism, which is mediated by tissue esterases. While propofol does not take long to take effect, it may cause some patients to experience a postponement of recovery because to its extended context-sensitive half-life [13-14].

Both medications were equally successful in achieving appropriate sedation from a pharmacodynamic standpoint, since all patients achieved the goal MOAA/S score of 3 or below. Both groups had the same amount of time to feel the sedative effects of remimazolam, suggesting that it has a fast onset equivalent to propofol [16]. Nevertheless, remimazolam demonstrated a notable benefit in relation to the reduced recovery time (8.5 ± 2.0 minutes versus 12.0 ± 3.0 minutes), a factor that holds great therapeutic significance in outpatient procedures such as colonoscopies, when prompt recovery and early release are desired [17].

When it comes to procedural sedation, hemodynamic stability is paramount. Remimazolam showed better cardiovascular stability than propofol in this trial, and the difference between the two was a much smaller drop in systolic blood pressure. The remimazolam group also had a decreased incidence of hypotension. These results are in line with the pharmacological profile of benzodiazepines, which are known to have minimal effects on the circulatory system compared to propofol [18-20].

When it comes to sedation, respiratory safety is of the utmost importance. Respiratory depression and oxygen desaturation were more common in the propofol group, while remimazolam kept respiratory stability better, according to this study. Because of this, remimazolam is especially helpful for people who are more likely to experience respiratory compromise [21-23].

Injection pain, hypotension, and the requirement for breathing support were less common with remimazolam than with propofol, according to the study's authors. Noteworthy, although propofol-induced pain is a typical and severe side effect, the remimazolam group did not experience injection discomfort. Moreover, remimazolam's safety profile is further improved by the availability of a specialized reversal drug, flumazenil [24-26].

This study's PK-PD modeling showed that the concentration-effect connection for both agents was predicted. Remimazolam, on the other hand, had a longer window of opportunity for therapeutic sedation, which meant it was safer and more effective than other options. Individualized dosing and enhanced patient safety are both aided by this predictability [27].

This study shows that remimazolam has a better pharmacokinetic-pharmacodynamic profile than propofol and is a safe and effective alternative for procedural sedation during colonoscopies. Because of its fast recovery time and rapid onset of sedation (on par with propofol), it is ideal for mobile treatments. Remimazolam improved patient safety with its reduced respiratory depression and greater hemodynamic stability. Less hypotension, injection discomfort, and the requirement for breathing assistance were among the adverse events that were linked to it. The pharmacokinetics of remimazolam make its sedation profile predictable and manageable, thanks to its faster clearance and shorter elimination half-life. Funding None Conflict of Interest: None

1. Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol. 2020;33(4):506–11.
2. Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I study of remimazolam. Anesth Analg. 2012;115(2):274–83.
3. Borkett KM, Riff DS, Schwartz HI, Winkle PJ, Pambianco DJ, Lees JP, et al. Phase III trial of remimazolam in colonoscopy. Gastrointest Endosc. 2018;88(3):427–37.
4. Rex DK, Bhandari R, Desta T, DeMicco M, Schaeffer C, Etzkorn K, et al. Remimazolam vs placebo and midazolam for sedation in colonoscopy. Gastroenterology. 2018;155(5):1356–67.
5. Pambianco DJ, Borkett KM, Riff DS, Winkle PJ, Schwartz HI, Melson TI, et al. Remimazolam for colonoscopy sedation: Phase III study. Gastrointest Endosc. 2016;83(5):984–92.
6. Keam SJ. Remimazolam: First approval. Drugs. 2020;80(6):625–33.
7. Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, et al. CNS 7056: A novel ultra–short-acting benzodiazepine. J Med Chem. 2007;50(20):4851–4.
8. Zhou Y, Hu P, Jiang J. Pharmacokinetic profile of remimazolam. Clin Pharmacokinet. 2020;59(3):267–79.
9. Chen SH, Yuan TM, Zhang J, Bai H, Tian M. Remimazolam vs propofol for procedural sedation: Systematic review. J Clin Anesth. 2021;71:110223.
10. Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T. Efficacy and safety of remimazolam vs propofol. J Anesth. 2020;34(4):543–53.
11. Liu T, Lai T, Chen J, Lu Y, He F, Chen Y, et al. Remimazolam vs propofol for sedation: Meta-analysis. Front Pharmacol. 2021;12:645.
12. Sneyd JR. Propofol and the development of anesthesia. Best Pract Res Clin Anaesthesiol. 2018;32(1):1–8.
13. Sahinovic MM, Struys MM, Absalom AR. Clinical pharmacokinetics and pharmacodynamics of propofol. Clin Pharmacokinet. 2018;57(12):1539–58.
14. Struys MM, De Smet T, Glen JI, Vereecke HE, Absalom AR, Schnider TW. Population pharmacokinetic modeling of propofol. Anesthesiology. 2004;100(4):1048–58.
15. Egan TD. Pharmacokinetics and pharmacodynamics of propofol. Clin Pharmacokinet. 1995;29(4):257–74.
16. Absalom AR, Mani V, De Smet T, Struys MM. Pharmacokinetic models for propofol. Br J Anaesth. 2009;103(1):26–37.
17. Bryson HM, Fulton BR, Faulds D. Propofol: Pharmacology and clinical use. Drugs. 1995;50(3):513–59.
18. Rex DK, Overley C, Kinser K, Coates M, Lee A, Goodwine BW, et al. Safety of propofol sedation in colonoscopy. Gastrointest Endosc. 2009;70(6):1115–20.
19. Vargo JJ, Zuccaro G Jr, Dumot JA, Shermock KM, Morrow JB, Shay SS, et al. Automated propofol sedation system. Gastroenterology. 2002;123(1):8–16.
20. Riphaus A, Wehrmann T, Weber B, Arnold J, Beilenhoff U, Bitter H, et al. S3 guidelines for sedation in GI endoscopy. Endoscopy. 2009;41(9):787–815.
21. Early DS, Lightdale JR, Vargo JJ, Acosta RD, Chandrasekhara V, Chathadi KV, et al. Guidelines for sedation in GI endoscopy. Gastrointest Endosc. 2018;87(2):327–37.
22. Mason KP, Green SM, Piacevoli Q. Adverse event reporting in pediatric sedation. Anesth Analg. 2012;114(4):1056–65.
23. Cohen LB. Sedation issues in endoscopy. Gastrointest Endosc Clin N Am. 2008;18(4):715–31.
24. Leslie K, Sessler DI, Schroeder M, Walters K. Propofol blood concentration and sedation depth. Anesthesiology. 1995;82(2):342–9.
25. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of benzodiazepines. Clin Pharmacokinet. 1983;8(3):233–52.
26. Wiltshire HR, Kilpatrick GJ, Tilbrook GS, Borkett KM. Metabolism and elimination of remimazolam. Drug Metab Dispos. 2012;40(12):2253–60.
27. Rex DK, DeMicco MP, Schaeffer C, Etzkorn K, Schreiber MJ, Pruitt R, et al. Remimazolam vs propofol for colonoscopy sedation. Gastrointest Endosc. 2021;94(1):40–51.